If my supposition is correct that GENR and OXGN are talking to some of the same prospective AMD partners, imagine how much better the negotiating position of these two companies would be if they were combined and thereby possessed both of the most promising systemically administered drugs for AMD…
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.